FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3001122348> ?p ?o ?g. }

• W3001122348 endingPage "123" @default.
• W3001122348 startingPage "122" @default.
• W3001122348 abstract "Few case studies have indicated that rituximab may be helpful in achieving clinical and serologic remission of dermatitis herpetiformis. We present a case of a 47-year-old man with celiac disease refractory to standard treatments who achieved clinical resolution of dermatitis herpetiformis with rituximab. A 47-year-old man with a history of celiac disease, vitiligo, type 1 diabetes mellitus, warm autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (also known as Evans syndrome) presented after splenectomy with pruritic rash and worsening hemolytic anemia and thrombocytopenia. Despite attempts at strict adherence to a gluten-free diet, his rash, composed of erythematous plaques scattered on bilateral extensor surfaces, buttocks, head, neck, abdomen, and groin, was worsening. Before presentation, the patient had intermittent flares of pruritic papules and vesicles on the extensor surfaces of the upper and lower extremities and buttocks after ingesting gluten, coinciding with dyspepsia, diarrhea, bloating, and nausea. Two days before presentation, he went to an outside urgent care clinic for worsening rash and yellowing skin, at which time his temperature was 37.8°C and he had elevated unconjugated hyperbilirubinemia at 3.7 mg/dL, which was concerning for active hemolysis. He was treated with intravenous diphenhydramine and intravenous ondansetron and was instructed to take oral hydroxyzine and loratadine for pruritus and apply topical triamcinolone 0.1% ointment twice daily as needed. His symptoms of rash and pruritus were not alleviated and continued to progress. Upon admission, a dermatology specialist was consulted, and 2 4-mm punch biopsy specimens were taken from the right flank for hematoxylin-eosin staining and direct immunofluorescence. Histopathologic analysis showed papillary dermal edema with neutrophilic inflammation, and direct immunofluorescence showed 2+ granular IgA deposition within the papillary dermis, consistent with dermatitis herpetiformis. Laboratory test results were significant for hematocrit of 35.5% (hemoglobin, 12.8 g/dL), platelet count of 437 000/μL, and total bilirubin of 4 mg/dL (direct bilirubin, 0.3 mg/dL), as well as prior positive warm and cold autoantibodies (Coombs positive, with 3+ C3 and 1+ IgG), which was concerning for ongoing hemolysis. The patient's hemoglobin A1c was 8.2%. Throughout the hospitalization, the patient had difficulty sleeping because of significant pruritus and further dissemination of his dermatitis herpetiformis lesions. Treatment with dapsone was considered but was not feasible due to continued hemolysis. The patient was started on high-dose prednisone at 80 mg (1 mg/kg) daily. His prednisone dose was increased to 120 mg (1.5 mg/kg) daily on his second day of hospitalization because of further progression. In the setting of high-dose steroids, the patient's blood glucose levels were extremely labile, despite up-titration of basal and sliding-scale insulin ranging between 90 and 400 mg/dL. The decision was made to start rituximab and taper prednisone. The patient was started on rituximab at 375 mg/m2 per week for 4 weeks according to the lymphoma protocol. He was discharged home after his first dose. He was readmitted after his second rituximab dose the following week because of worsening anemia, with hematocrit of 23.1% (hemoglobin, 7.8 g/dL), platelets at 437 000 K/μL, and resurfacing of his dermatitis herpetiformis due to likely unintentional gluten exposure. He was given dexamethasone 40 mg daily and started mycophenolate mofetil 500 mg twice daily as a steroid-sparing agent because of labile blood glucose. Upon discharge, the patient's autoimmune hemolytic anemia had resolved and dermatitis herpetiformis was quiescent, so dexamethasone was stopped after 4 days and mycophenolate mofetil after 5 days. He continued to be stable and clear while receiving his third and fourth doses of rituximab. He experienced complete clinical remission of his autoimmune hemolytic anemia and significant improvement in his celiac and dermatitis herpetiformis while adhering to a gluten-free diet. His follow-up hematocrit level almost 4 months after treatment was 43.6% (hemoglobin, 14.9 g/dL), with a total bilirubin level of 1.4 mg/dL and platelets at 455 000/μL. Gluten avoidance is the criterion standard in treatment for dermatitis herpetiformis and the intestinal gluten-sensitive enteropathy of the usually associated celiac disease. Cases refractory to gluten-free diet often require dapsone or sulfapyridine therapy. Despite significant pruritus and widespread dermatitis significantly affecting our patient's quality of life, dapsone therapy was not feasible in our patient in the setting of hyperbilirubinemia and active hemolytic anemia. Case report studies suggest that rituximab for celiac disease may be successful.1Nikiphorou E. Hall F.C. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.Rheumatology (Oxford). 2014; 53: 1906-1907Crossref PubMed Scopus (4) Google Scholar,2Palazzo C. Nicaise-Roland P. Palazzo E. Rituximab: an effective treatment for rheumatologic and digestive symptoms of celiac disease?.Joint Bone Spine. 2012; 79: 422-423Crossref PubMed Scopus (6) Google Scholar Similarly, Go et al3Go R.S. Winters J.L. Kay N.E. How I treat autoimmune hemolytic anemia.Blood. 2017; 129: 2971-2979Crossref PubMed Scopus (72) Google Scholar showed that refractory cases of AIHA may be treated with rituximab with varying degrees of success. Furthermore, Albers et al4Albers L.N. Zone J.J. Stoff B.K. Feldman R.J. Rituximab treatment for recalcitrant dermatitis herpetiformis.JAMA Dermatol. 2017; 153: 315-318Crossref PubMed Scopus (19) Google Scholar reported an 80-year-old man successfully treated to achieve clinical and serologic resolution of dermatitis herpetiformis (test results for transglutaminase 2 and 3 were negative after 13 months of therapy) with rituximab after failure of high-dose prednisone and azathioprine. Our patient's situation was complicated by Evans syndrome and steroid-induced hyperglycemia, which made standard treatment even more difficult. After treatment with rituximab, our patient experienced improvement in both his dermatitis herpetiformis in the setting of celiac disease as well as in his AIHA. He also has a theoretical lowered risk of mucosa-associated lymphoid tissue lymphoma, because there is no longer a mechanism of inflammation with the targeted loss of CD20+ cells and memory B cells from treatment.5Conconi A. Martinelli G. Thiéblemont C. et al.Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.Blood. 2003; 102: 2741-2745Crossref PubMed Scopus (328) Google Scholar In our patient's case, rituximab proved to be effective therapy, as reported during follow-up. Although he reports occasional minor flares of dermatitis herpetiformis, he denies any widespread involvement, and his hemoglobin and platelet counts remain stable. This suggests that rituximab for dermatitis herpetiformis in the setting of autoimmune disease may be an effective treatment option." @default.
• W3001122348 created "2020-01-30" @default.
• W3001122348 creator A5012533956 @default.
• W3001122348 creator A5046302800 @default.
• W3001122348 creator A5068238837 @default.
• W3001122348 date "2020-02-01" @default.
• W3001122348 modified "2023-10-16" @default.
• W3001122348 title "Rituximab treatment for dermatitis herpetiformis in the setting of type 1 diabetes mellitus, celiac disease, vitiligo, autoimmune hemolytic anemia, and autoimmune thrombocytopenia" @default.
• W3001122348 cites W2083294272 @default.
• W3001122348 cites W2142372281 @default.
• W3001122348 cites W2148613364 @default.
• W3001122348 cites W2567313154 @default.
• W3001122348 cites W2600140285 @default.
• W3001122348 doi "https://doi.org/10.1016/j.jdcr.2019.12.007" @default.
• W3001122348 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6992878" @default.
• W3001122348 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32016156" @default.
• W3001122348 hasPublicationYear "2020" @default.
• W3001122348 type Work @default.
• W3001122348 sameAs 3001122348 @default.
• W3001122348 citedByCount "2" @default.
• W3001122348 countsByYear W30011223482020 @default.
• W3001122348 countsByYear W30011223482022 @default.
• W3001122348 crossrefType "journal-article" @default.
• W3001122348 hasAuthorship W3001122348A5012533956 @default.
• W3001122348 hasAuthorship W3001122348A5046302800 @default.
• W3001122348 hasAuthorship W3001122348A5068238837 @default.
• W3001122348 hasBestOaLocation W30011223481 @default.
• W3001122348 hasConcept C126322002 @default.
• W3001122348 hasConcept C134018914 @default.
• W3001122348 hasConcept C159654299 @default.
• W3001122348 hasConcept C16005928 @default.
• W3001122348 hasConcept C163764329 @default.
• W3001122348 hasConcept C203014093 @default.
• W3001122348 hasConcept C2777385706 @default.
• W3001122348 hasConcept C2778728583 @default.
• W3001122348 hasConcept C2779075594 @default.
• W3001122348 hasConcept C2779134260 @default.
• W3001122348 hasConcept C2779338263 @default.
• W3001122348 hasConcept C2779980618 @default.
• W3001122348 hasConcept C2780130043 @default.
• W3001122348 hasConcept C2780653079 @default.
• W3001122348 hasConcept C2781232474 @default.
• W3001122348 hasConcept C555293320 @default.
• W3001122348 hasConcept C71924100 @default.
• W3001122348 hasConceptScore W3001122348C126322002 @default.
• W3001122348 hasConceptScore W3001122348C134018914 @default.
• W3001122348 hasConceptScore W3001122348C159654299 @default.
• W3001122348 hasConceptScore W3001122348C16005928 @default.
• W3001122348 hasConceptScore W3001122348C163764329 @default.
• W3001122348 hasConceptScore W3001122348C203014093 @default.
• W3001122348 hasConceptScore W3001122348C2777385706 @default.
• W3001122348 hasConceptScore W3001122348C2778728583 @default.
• W3001122348 hasConceptScore W3001122348C2779075594 @default.
• W3001122348 hasConceptScore W3001122348C2779134260 @default.
• W3001122348 hasConceptScore W3001122348C2779338263 @default.
• W3001122348 hasConceptScore W3001122348C2779980618 @default.
• W3001122348 hasConceptScore W3001122348C2780130043 @default.
• W3001122348 hasConceptScore W3001122348C2780653079 @default.
• W3001122348 hasConceptScore W3001122348C2781232474 @default.
• W3001122348 hasConceptScore W3001122348C555293320 @default.
• W3001122348 hasConceptScore W3001122348C71924100 @default.
• W3001122348 hasIssue "2" @default.
• W3001122348 hasLocation W30011223481 @default.
• W3001122348 hasLocation W30011223482 @default.
• W3001122348 hasLocation W30011223483 @default.
• W3001122348 hasLocation W30011223484 @default.
• W3001122348 hasLocation W30011223485 @default.
• W3001122348 hasOpenAccess W3001122348 @default.
• W3001122348 hasPrimaryLocation W30011223481 @default.
• W3001122348 hasRelatedWork W1482119672 @default.
• W3001122348 hasRelatedWork W1484311423 @default.
• W3001122348 hasRelatedWork W1833396630 @default.
• W3001122348 hasRelatedWork W1976309343 @default.
• W3001122348 hasRelatedWork W199962162 @default.
• W3001122348 hasRelatedWork W2008299940 @default.
• W3001122348 hasRelatedWork W2043428857 @default.
• W3001122348 hasRelatedWork W2511854298 @default.
• W3001122348 hasRelatedWork W2384405194 @default.
• W3001122348 hasRelatedWork W291428212 @default.
• W3001122348 hasVolume "6" @default.
• W3001122348 isParatext "false" @default.
• W3001122348 isRetracted "false" @default.
• W3001122348 magId "3001122348" @default.
• W3001122348 workType "article" @default.